SG11201909041SA - Anti-pd-l1 antibody and use thereof - Google Patents
Anti-pd-l1 antibody and use thereofInfo
- Publication number
- SG11201909041SA SG11201909041SA SG11201909041SA SG11201909041SA SG 11201909041S A SG11201909041S A SG 11201909041SA SG 11201909041S A SG11201909041S A SG 11201909041SA SG 11201909041S A SG11201909041S A SG 11201909041SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- moscow
- pct
- antibodies
- fully human
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
CMarotta' nub .45-1 AA.Phstrort • • 71 , Seri Eor Ege-551 5srscr chip OR cents W O 20 18/ 195 226 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 25 October 2018 (25.10.2018) WIPO I PCT omits otiolom omullom mom° an (10) International Publication Number WO 2018/195226 Al (51) International Patent Classification: C07K 16/28 (2006.01) Cl 2N 15/13 (2006.01) C12N 15/63 (2006.01) A61K 39/395 (2006.01) (21) International Application Number: PCT/US2018/028206 (22) International Filing Date: 18 April 2018 (18.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: PCT/US2017/028206 18 April 2017 (18.04.2017) US (71) Applicant: R-PHARM OVERSEAS, INC. [US/US]; 12526 High Bluff Dr. Ste 300, San Diego, CA 92130 (US). (72) Inventors: LAVROVSKY, Yan; 1969 Zapo Street, Del Mar, CA 92014 (US). XU, Ting; 67 Wayne Road, Need- ham, MA 02492 (US). BARBASHOV, Sergei; 31105 Quail Meadows, Irvine, CA 902603 (US). REPIK, Alex- ey; 3 Osenniy Boulevard, Apt. 106, Moscow, 121609 (RU). SAMSONOV, Mikhail; 74-6-77 Leningradsky Prospect, Moscow, 125313 (RU). IGNATIEV, Vasily; 13 Skolkovskoye Shosse, Apt. 212, Moscow, 121353 (RU). ARCHUADZE, Shorena; 19/2 Institutskaya Street, Apt.34, Mitischi, Moscow, 141002 (RU). (74) Agent: KORKHIN, Yakov, M.; SciTech Legal PC, PO Box 15696, Boston, MA 02215 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (54) Title: ANTI-PD-L1 ANTIBODY AND USE THEREOF (57) : Disclosed are fully human anti-PD-Ll antibodies and their corresponding applications. Fully human antibodies are capable of specifi- cally binding to human PD-L1. Antibodies were obtained by employing a yeast display library-based screening technique and also by affmity matura- M.,55.1 /OR dt tezatizurneb tion to further improve their affinity for PD-L1. The fully human anti-PD-Ll antibodies disclosed show good specificity, affmity and stability. They are capable of enhancing T cell activity by binding to activated T cells, while significantly inhibiting tumor growth. Disclosed fully human anti-PD-Ll an- tibodies can be used in the diagnosis and treatment of PD-Ll-related cancers and other associated diseases. Figure 17 [Continued on next page] WO 2018/195226 Al MIDEDIMONEMIEFIEDERIMIDEEMIEOHEVOIS Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a))
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2017028206 | 2017-04-18 | ||
PCT/US2018/028206 WO2018195226A1 (en) | 2017-04-18 | 2018-04-18 | Anti-pd-l1 antibody and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201909041SA true SG11201909041SA (en) | 2019-11-28 |
Family
ID=63856823
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201909041S SG11201909041SA (en) | 2017-04-18 | 2018-04-18 | Anti-pd-l1 antibody and use thereof |
Country Status (16)
Country | Link |
---|---|
US (1) | US20210115143A1 (en) |
EP (1) | EP3612565A4 (en) |
JP (2) | JP2020517239A (en) |
KR (1) | KR102323960B1 (en) |
CN (1) | CN110856446A (en) |
AU (1) | AU2018256392B2 (en) |
BR (1) | BR112019021828B1 (en) |
CA (1) | CA3059447A1 (en) |
CL (1) | CL2019002953A1 (en) |
CO (1) | CO2019012118A2 (en) |
EA (1) | EA201900443A1 (en) |
MA (1) | MA50038A (en) |
MX (1) | MX2019012461A (en) |
PH (1) | PH12019502302A1 (en) |
SG (1) | SG11201909041SA (en) |
WO (1) | WO2018195226A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
WO2020102603A1 (en) * | 2018-11-14 | 2020-05-22 | Rubryc Therapeutics, Inc. | Engineered cd25 polypeptides and uses thereof |
CN109929037B (en) * | 2019-04-01 | 2023-03-17 | 华博生物医药技术(上海)有限公司 | Conjugates to programmed death ligands and uses thereof |
AU2020271467B2 (en) * | 2019-04-11 | 2024-06-27 | Scripps Korea Antibody Institute | Antibodies against programmed death-ligand 1 and uses thereof |
WO2020216379A1 (en) * | 2019-04-26 | 2020-10-29 | I-Mab | Human pd-l1 antibodies |
WO2022006091A1 (en) * | 2020-06-29 | 2022-01-06 | Anovent Pharmaceutical (U.S.), Llc | Biopharmaceutical formulation of anti-pd-1, anti-pd-l1, and anti-vegfr therapeutic monoclonal antibodies and method for treating nsclc by inhalation |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030113316A1 (en) * | 2001-07-25 | 2003-06-19 | Kaisheva Elizabet A. | Stable lyophilized pharmaceutical formulation of IgG antibodies |
CN108997498A (en) * | 2008-12-09 | 2018-12-14 | 霍夫曼-拉罗奇有限公司 | Anti- PD-L1 antibody and they be used to enhance the purposes of T cell function |
AU2014339900B2 (en) * | 2013-10-25 | 2019-10-24 | Dana-Farber Cancer Institute, Inc. | Anti-PD-L1 monoclonal antibodies and fragments thereof |
EP3092004A4 (en) * | 2014-01-06 | 2017-02-22 | The Trustees Of The University Of Pennsylvania | Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy |
WO2015127288A1 (en) * | 2014-02-20 | 2015-08-27 | Alder Biopharmaceuticals, Inc. | Anti-acth antibodies and use thereof |
CN105777906B (en) * | 2014-12-19 | 2019-04-23 | 苏州丁孚靶点生物技术有限公司 | Anti- PD-L1 human antibody and its application |
BR112017019559B1 (en) * | 2015-03-13 | 2020-08-04 | Cytomx Therapeutics, Inc | ANTI-PDL1 ANTIBODIES, ACTIVABLE ANTI-PDL1 ANTIBODIES, AND METHODS OF USE OF THESE |
AU2017348475B2 (en) * | 2016-10-30 | 2024-02-08 | Shanghai Henlius Biotech, Inc. | Anti-PD-L1 antibodies and variants |
-
2018
- 2018-04-18 EP EP18788069.5A patent/EP3612565A4/en active Pending
- 2018-04-18 JP JP2019556600A patent/JP2020517239A/en active Pending
- 2018-04-18 SG SG11201909041S patent/SG11201909041SA/en unknown
- 2018-04-18 CA CA3059447A patent/CA3059447A1/en active Pending
- 2018-04-18 WO PCT/US2018/028206 patent/WO2018195226A1/en unknown
- 2018-04-18 US US16/606,647 patent/US20210115143A1/en not_active Abandoned
- 2018-04-18 AU AU2018256392A patent/AU2018256392B2/en active Active
- 2018-04-18 EA EA201900443A patent/EA201900443A1/en unknown
- 2018-04-18 BR BR112019021828-9A patent/BR112019021828B1/en active IP Right Grant
- 2018-04-18 KR KR1020197032419A patent/KR102323960B1/en active IP Right Grant
- 2018-04-18 MX MX2019012461A patent/MX2019012461A/en unknown
- 2018-04-18 MA MA050038A patent/MA50038A/en unknown
- 2018-04-18 CN CN201880025898.4A patent/CN110856446A/en active Pending
-
2019
- 2019-10-07 PH PH12019502302A patent/PH12019502302A1/en unknown
- 2019-10-16 CL CL2019002953A patent/CL2019002953A1/en unknown
- 2019-10-29 CO CONC2019/0012118A patent/CO2019012118A2/en unknown
-
2022
- 2022-11-07 JP JP2022178282A patent/JP2023025003A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR102323960B1 (en) | 2021-11-10 |
CL2019002953A1 (en) | 2020-01-10 |
EA201900443A1 (en) | 2020-03-06 |
CO2019012118A2 (en) | 2020-04-01 |
US20210115143A1 (en) | 2021-04-22 |
KR20190141169A (en) | 2019-12-23 |
JP2020517239A (en) | 2020-06-18 |
AU2018256392A1 (en) | 2019-10-17 |
MX2019012461A (en) | 2019-12-11 |
PH12019502302A1 (en) | 2020-09-21 |
EP3612565A1 (en) | 2020-02-26 |
EP3612565A4 (en) | 2021-06-16 |
MA50038A (en) | 2020-07-08 |
JP2023025003A (en) | 2023-02-21 |
AU2018256392B2 (en) | 2024-05-16 |
CN110856446A (en) | 2020-02-28 |
CA3059447A1 (en) | 2018-10-25 |
BR112019021828B1 (en) | 2022-09-20 |
WO2018195226A1 (en) | 2018-10-25 |
BR112019021828A2 (en) | 2020-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201909041SA (en) | Anti-pd-l1 antibody and use thereof | |
SG11201906192SA (en) | Methods of treating cancer with anti-pd-1 antibodies | |
SG11201805320XA (en) | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration | |
SG11201809554VA (en) | Methods of treating skin cancer by administering a pd-1 inhibitor | |
SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
SG11201903454VA (en) | Immunologically discernible cell surface variants for use in cell therapy | |
SG11201907753TA (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
SG11201811432WA (en) | Rna for cancer therapy | |
SG11201908971RA (en) | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene | |
SG11201906468TA (en) | Chimeric antigen receptors against axl or ror2 and methods of use thereof | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201909949XA (en) | Targeted immunotolerance | |
SG11201903771XA (en) | Binding molecules specific for asct2 and uses thereof | |
SG11201904535VA (en) | Prevention and treatment of bone and cartilage damage or disease | |
SG11201901834WA (en) | Micrornas as biomarkers for endometriosis | |
SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201901996UA (en) | Formulations of ( r)-2-amino-3-phenylpropyl carbamate | |
SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
SG11201803703UA (en) | Anti-complement factor c1q fab fragments and uses thereof | |
SG11201408787PA (en) | Enhancing activity of car t cells by co-introducing a bispecific antibody | |
SG11201809751XA (en) | Egfr inhibitor compounds | |
SG11201407417VA (en) | Encoding and reconstruction of residual data based on support information | |
SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
SG11201900361RA (en) | Methods of treating prostate cancer |